image: A team of researchers from the Research Institute of the McGill University Health Center (RI-MUHC) found that elevations in a unusual form of cholesterol, called Lipoprotein(a) or Lp(a), as responsible for 1 in 14 heart attacks and 1 in 7 cases of aortic valve disease. This form of cholesterol is not commonly screened for in Canada, so most people do not even know they are at risk. Although no specific treatments exist to lower Lp(a), new therapies are being developed, and in addition to this study, the researchers hope to demonstrate how lowering this form of cholesterol could have an important impact on the population. view more
Credit: McGill University Health Center
Montreal, Feb. 22, 2017 - A team of researchers from the Research Institute of the McGill University Health Center (RI-MUHC) found that elevations in a unusual form of cholesterol, called Lipoprotein(a) or Lp(a), as responsible for 1 in 14 heart attacks and 1 in 7 cases of aortic valve disease. This form of cholesterol is not commonly screened for in Canada, so most people do not even know they are at risk. Although no specific treatments exist to lower Lp(a), new therapies are being developed, and in addition to this study, the researchers hope to demonstrate how lowering this form of cholesterol could have an important impact on the population."Approximately 20 per cent of individuals have high Lp (a), a form of cholesterol that is highly heritable and runs in families," says Dr. George Thanassoulis, who is a researcher at the RI-MUHC and principal author of the study "We hope that our work will raise awareness that individuals with high Lp(a) are at high risk of heart disease and hopefully stimulate the development and testing of new therapies."
###
About the study
The study Estimating the Population Impact of Lp(a) Lowering on the Incidence of Myocardial Infarction and Aortic Stenosis was co-written by Mehdi Afshar, Pia R. Kamstrup, Ken Williams, Allan D. Sniderman, Børge G. Nordestgaard and George Thanassoulis, and is published in the journal Arteriosclerosis, Thrombosis, and Vascular Biology.